Bristol-Myers Squibb Company
Bristol-Myers Squibb Company
Your view on BMY
Overview
What the company does, where it operates, and who runs it.
About Bristol-Myers Squibb Company
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- CEO
- Christopher S. Boerner
- Headquarters
- 430 East 29th Street, Princeton, NY, US
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- CEO
- Christopher S. Boerner
- Headquarters
- 430 East 29th Street, Princeton, NY, US
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases.
The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis.
It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma.
In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML.
It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Stock Data
Price chart, volume, and trading data.
What moved it
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for Bristol-Myers Squibb Company from FRC's valuation model, read against the market price. BMY last traded at $63.43, 14.1× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Bristol-Myers Squibb Company. Starting points for Bristol-Myers Squibb Company: P/E 14.1, EPS $4.52, beta 0.23 — an Drug Manufacturers - General name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Bristol-Myers Squibb Company. Bristol-Myers Squibb Company paid $2.52 per share over the last year — a 4.0% yield at the current $63.43 price. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Bristol-Myers Squibb Company. Trailing twelve-month EPS for Bristol-Myers Squibb Company stands at $4.52. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Current price
—
live quote
Analysts' target
$66.53
average of 17 firms, last 12 months
Analyst Ratings
- Strong Buy0
- Buy7
- Hold8
- Sell1
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $1.50 | $1.52 | $6.44 | $6.70 |
| Low estimate | $1.42 | $1.38 | $6.15 | $6.14 |
| High estimate | $1.60 | $1.65 | $6.83 | $7.26 |
| No. of analysts | 15 | 7 | 16 | 17 |
| Year-ago EPS | $1.26 | $1.58 | $3.45 | — |
| Growth | +19.0% | -3.7% | +86.8% | — |
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $12.66B | $11.33B | $50.17B | $48.83B |
| Low estimate | $12.49B | $10.96B | $49.70B | $47.52B |
| High estimate | $12.95B | $11.64B | $50.62B | $50.80B |
| No. of analysts | 13 | 5 | 19 | 20 |
| Year-ago revenue | $12.50B | $11.49B | $48.20B | — |
| Growth | +1.3% | -1.4% | +4.1% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga, Pulse 2.0; as of Nov 13, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Bristol-Myers Squibb Company. Bristol-Myers Squibb Company has reported as a listed company since 1972. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Peer companies
Market cap
- ABBVAbbVie Inc.Drug Manufacturers - General$521.5B
- AMGNAmgen Inc.Drug Manufacturers - General$252.6B
- AZNAstraZeneca PLCDrug Manufacturers - General$286.1B
- GILDGilead Sciences, Inc.Drug Manufacturers - General$208.5B
- GSKGSK plcDrug Manufacturers - General$102.2B
- JNJJohnson & JohnsonDrug Manufacturers - General$687.9B
- LLYEli Lilly and CompanyDrug Manufacturers - General$1.4T
- MRKMerck & Co., Inc.Drug Manufacturers - General$364.3B
More Drug Manufacturers - General companies
- ALPMFAstellas Pharma Inc.OTC$28.1B
- ALPMYAstellas Pharma Inc.OTC$29.2B
- AMRNAmarin Corporation plcNASDAQ$241M
- BAYRYBayer AGOTC$49.0B
- BIIBBiogen Inc.NASDAQ$37.0B
- CHGCFChugai Pharmaceutical Co., Ltd.OTC$105.3B
- CHGCYChugai Pharmaceutical Co., Ltd.OTC$110.0B
- CHJTFCSPC Pharmaceutical Group LimitedOTC$15.8B
- CSPCYCSPC Pharmaceutical Group LimitedOTC$14.6B
ETFs holding Bristol-Myers Squibb Company
% of the fund
- VTIVanguard Total Stock Market ETF$689.2B in assets0.17%
- SCHDSchwab U.S. Dividend Equity ETF$119.9B in assets2.99%
- VOOVanguard S&P 500 ETF$1.0T in assets0.19%
- XUU.TOiShares Core S&P U.S. Total Market Index ETF$4.6B in assets0.18%
- IVViShares Core SP 500 ETF$852.9B in assets0.20%
- HHL.TOHarvest Healthcare Leaders Income ETF$2.2B in assets5.09%
- PPHVanEck Pharmaceutical ETF$1.1B in assets4.41%
- IHEiShares US Pharmaceuticals ETF$1.7B in assets4.04%
Largest holders first, then the funds most concentrated in BMY.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Bristol-Myers Squibb Company, and how their positions are changing. At a $129.66B market value, institutional positions materially move Bristol-Myers Squibb Company's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Bristol-Myers Squibb Company executives and directors. Shares of Bristol-Myers Squibb Company have traded between $42.52 and $63.33 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
About this section
U.S. Senate disclosures naming Bristol-Myers Squibb Company. Bristol-Myers Squibb Company is a $129.66B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
About this section
U.S. House of Representatives disclosures naming Bristol-Myers Squibb Company. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Bristol-Myers Squibb Company. Coverage tracks Bristol-Myers Squibb Company within Drug Manufacturers - General (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Bristol-Myers Squibb Company.